Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (In-FI)
Comparison of Postprandial Glycemic Control in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus Using Novolog vs. Fiasp Insulin: a Randomized Controlled Open Label Trial
Sponsor: Boston Medical Center
A PHASE3 clinical study on Type 2 Diabetes Treated With Insulin, this trial is completed. The trial is conducted by Boston Medical Center and has accumulated 11 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Apr 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
May 2023 — Jan 2024 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Jun 2022 — May 2023 [monthly]
Recruiting PHASE3
-
Jan 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boston Medical Center
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .